Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

Autor:	Yitian Zhou, Magnus Ingelman-Sundberg, Volker M. Lauschke
Rok vydání:	2019
Předmět:	0301 basic medicine SJS Stevens-Johnson syndrome DNMTs DNA methyltransferases PTMs Posttranslational modifications Epigenesis Genetic TAB-Seq TET-assisted bisulfite sequencing MAF Minor allele frequencies SCAR Severe cutaneous adverse reaction 0302 clinical medicine ChIP Chromatin immunoprecipitation CFTR Cystic fibrosis transmembrane conductance regulator Medicine eQTL Quantitative trait locus Pharmacology (medical) Biomarker discovery PRC2 Polycomb repressive complex 2 5hmC 5-hydroxymethylcytosine UM Ultrarapid metabolism education.field_of_study MS Multiple sclerosis High-Throughput Nucleotide Sequencing TEN Toxic epidermal necrolysis Biobank CPIC Clinical Pharmacogenetics Implementation Consortium 3. Good health PM Poor metabolism 030220 oncology & carcinogenesis GST Glutathione-S-transferase SNVs Single nucleotide variations DIHS Drug-induced hypersensitivity syndrome Drug-Related Side Effects and Adverse Reactions 5fC 5- Formylcytosine Population MEDLINE 5caC 5- Carboxylcytosine DPWG Dutch Pharmacogenetics Working Group Article 03 medical and health sciences HDACs Histone deacetylases RA Retinoic acid ABC-HSS Abacavir hypersensitivity syndrome Animals Humans Pharmacokinetics MPE Maculopapular exanthema education Pharmacology oxBS-seq Oxidative bisulfite sequencing business.industry DILI Drug-induced liver injury CNVs Copy number variations DRESS Drug rash with eosinophilia and systemic symptoms Data science CAT Catalase GPCR G-protein coupled receptor 030104 developmental biology ALL Acute lymphoblastic leukemia Biological Variation Population Pharmacogenetics Pharmacogenomics Genomic Profile Personalized medicine DHR Drug hypersensitivity reactions business Biomarkers
Zdroj:	Pharmacology & Therapeutics
ISSN:	0163-7258
DOI:	10.1016/j.pharmthera.2019.01.002
Popis:	Individuals differ substantially in their response to pharmacological treatment. Personalized medicine aspires to embrace these inter-individual differences and customize therapy by taking a wealth of patient-specific data into account. Pharmacogenomic constitutes a cornerstone of personalized medicine that provides therapeutic guidance based on the genomic profile of a given patient. Pharmacogenomics already has applications in the clinics, particularly in oncology, whereas future development in this area is needed in order to establish pharmacogenomic biomarkers as useful clinical tools. In this review we present an updated overview of current and emerging pharmacogenomic biomarkers in different therapeutic areas and critically discuss their potential to transform clinical care. Furthermore, we discuss opportunities of technological, methodological and institutional advances to improve biomarker discovery. We also summarize recent progress in our understanding of epigenetic effects on drug disposition and response, including a discussion of the only few pharmacogenomic biomarkers implemented into routine care. We anticipate, in part due to exciting rapid developments in Next Generation Sequencing technologies, machine learning methods and national biobanks, that the field will make great advances in the upcoming years towards unlocking the full potential of genomic data.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c77b497b32c4399ec51c1cb33968c9c https://doi.org/10.1016/j.pharmthera.2019.01.002 Zobrazit plný text záznamu Full Text from ScienceDirect